BRPI0812919B8 - composição farmacêutica que compreende um composto e kit - Google Patents
composição farmacêutica que compreende um composto e kitInfo
- Publication number
- BRPI0812919B8 BRPI0812919B8 BRPI0812919A BRPI0812919A BRPI0812919B8 BR PI0812919 B8 BRPI0812919 B8 BR PI0812919B8 BR PI0812919 A BRPI0812919 A BR PI0812919A BR PI0812919 A BRPI0812919 A BR PI0812919A BR PI0812919 B8 BRPI0812919 B8 BR PI0812919B8
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compound
- hypertension
- relates
- calcium channel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
bloqueadores de canal de cálcio de fenilalquilamina de ação curta e uso dos mesmos a presente invenção refere-se ao uso de uma quantidade farmaceuticamente eficaz de um composto cálcio de bloqueio de canal de cálcio de curta ação para tratar condição cardíaca isquêmica, arritmias cardíacas,crise hipertensiva em uma rotina de quarto de emergência, hipertensão antes, durante, ou depois de cirurgia, fenômeno de não-refluxo seguinte a reperfusão, e doenças associadas com fluxo sanguíneo de músculo esquelético diminuído. a invenção também se refere às composições farmacêuticas formuladas para uso em tais métodos e aos kits para tais métodos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93644007P | 2007-06-20 | 2007-06-20 | |
PCT/US2008/007665 WO2008156820A1 (en) | 2007-06-20 | 2008-06-19 | Short acting phenylalkylamine calcium channel blockers and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0812919A2 BRPI0812919A2 (pt) | 2014-10-07 |
BRPI0812919B1 BRPI0812919B1 (pt) | 2019-01-29 |
BRPI0812919B8 true BRPI0812919B8 (pt) | 2021-05-25 |
Family
ID=40156562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0812919A BRPI0812919B8 (pt) | 2007-06-20 | 2008-06-19 | composição farmacêutica que compreende um composto e kit |
Country Status (19)
Country | Link |
---|---|
US (16) | US20100190852A1 (pt) |
EP (1) | EP2170050B1 (pt) |
JP (1) | JP5421908B2 (pt) |
KR (1) | KR101541557B1 (pt) |
CN (1) | CN101754678B (pt) |
AU (1) | AU2008266798B2 (pt) |
BR (1) | BRPI0812919B8 (pt) |
CA (1) | CA2693627C (pt) |
CY (1) | CY1115619T1 (pt) |
DK (1) | DK2170050T3 (pt) |
ES (1) | ES2498047T3 (pt) |
HK (1) | HK1140913A1 (pt) |
HR (1) | HRP20140801T1 (pt) |
MX (1) | MX347325B (pt) |
NZ (1) | NZ582033A (pt) |
PL (1) | PL2170050T3 (pt) |
PT (1) | PT2170050E (pt) |
SI (1) | SI2170050T1 (pt) |
WO (1) | WO2008156820A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2498047T3 (es) | 2007-06-20 | 2014-09-24 | Milestone Pharmaceuticals Inc. | Bloqueantes de los canales de calcio de fenilalquilamina de acción corta y usos de los mismos |
KR101052620B1 (ko) * | 2008-08-28 | 2011-07-29 | 한국과학기술연구원 | 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 t-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물 |
KR20120100945A (ko) * | 2009-09-30 | 2012-09-12 | 마이크로도스 테라퓨특스, 인코포레이티드 | 레이노 증후군의 치료를 위한 방법들 및 조성물들 |
WO2015073919A1 (en) * | 2013-11-14 | 2015-05-21 | University Medical Pharmaceuticals Corporation | Microneedles for therapeutic agent delivery with improved mechanical properties |
BR112017021620B1 (pt) * | 2015-04-14 | 2023-10-03 | Milestone Pharmaceuticals Inc | Composição aquosa formulada para administração nasal, seu uso,sistema de liberação nasal e método de produção de uma solução formulada para administração nasal |
US20230065401A1 (en) * | 2021-07-15 | 2023-03-02 | Milestone Pharmaceuticals Inc. | Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1154810B (de) * | 1961-04-01 | 1963-09-26 | Knoll Ag | Verfahren zur Herstellung basisch substituierter Phenylacetonitrile |
US3957845A (en) * | 1962-04-27 | 1976-05-18 | Knoll A.G. Chemische Fabriken | Trifluoromethyl-substituted phenyl acetonitriles |
DE1493904A1 (de) * | 1965-07-31 | 1969-06-19 | Knoll Ag | Verfahren zur Herstellung basisch substituierter Phenylacetonitrile |
DE2059923C3 (de) * | 1970-12-05 | 1979-01-25 | Knoll Ag, 6700 Ludwigshafen | l-a-Isopropyl-o-[(N-methyl-N-homoveratryl)v-aminopropyl] -3,4-dimethoxyphenylacetonitril, Verfahren zu dessen Herstellung und dieses enthaltende Arzneimittel |
JPS5118940B2 (pt) | 1971-12-25 | 1976-06-14 | ||
DE2631222C3 (de) * | 1976-07-12 | 1979-01-04 | Knoll Ag, 6700 Ludwigshafen | Verfahren zur Herstellung basisch substituierter Phenylacetonitrile |
DE3144150A1 (de) * | 1981-04-10 | 1982-12-09 | Basf Ag, 6700 Ludwigshafen | (omega)-cyan-1,(omega)-diphenyl-azaalkan-derivate, ihre herstellung und diese enthaltende arzneimittel |
DE3433383A1 (de) * | 1984-09-12 | 1986-03-20 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue phenyl-acetonitril-derivate |
DE3603032A1 (de) * | 1986-01-31 | 1987-08-06 | Basf Ag | Basisch substituierte phenylacetonitrile, ihre herstellung und diese enthaltende arzneimittel |
US4833162A (en) * | 1988-02-03 | 1989-05-23 | American Cyanamid Company | Substituted benzeneacetonitriles and their use as calcium channel blockers |
PT96283A (pt) | 1989-12-21 | 1991-09-30 | Searle & Co | Metodos de utilizacao de 2-isopropil-2-fenilaminovaleronitrilos como imunossupressores e vasodilatadores |
US5162569A (en) | 1989-12-21 | 1992-11-10 | G. D. Searle & Co. | Phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives |
US5486539A (en) * | 1989-12-21 | 1996-01-23 | G. D. Searle & Co. | Method of using phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives |
US5247119A (en) * | 1990-12-12 | 1993-09-21 | G. D. Searle & Co. | Phenylacetonitrilehydroxyalkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives |
US6057344A (en) * | 1991-11-26 | 2000-05-02 | Sepracor, Inc. | Methods for treating hypertension, and angina using optically pure (-) amlodipine |
US5451604A (en) * | 1993-07-26 | 1995-09-19 | G. D. Searle & Co. | Halogenated phenylacetonitrile alkylaminoalkylphenyl compounds as immunosuppressives |
US5910601A (en) * | 1994-09-26 | 1999-06-08 | Darwin Discovery Limited | Chiral nitriles, their preparation and their use for the manufacture of verapamil and analogues |
US5859279A (en) | 1996-09-10 | 1999-01-12 | Darwin Discovery Limited | Compound and process |
US6750238B1 (en) | 2000-05-12 | 2004-06-15 | The University Of Toledo | Aralkyl ester soft drugs |
US7511077B2 (en) * | 2005-02-09 | 2009-03-31 | Neuromed Pharmaceuticals Ltd. | Diamine calcium channel blockers |
GB2435824A (en) | 2006-03-09 | 2007-09-12 | Esteve Labor Dr | Use of nitrile compounds in the treatment of food related and other disorders |
ES2498047T3 (es) | 2007-06-20 | 2014-09-24 | Milestone Pharmaceuticals Inc. | Bloqueantes de los canales de calcio de fenilalquilamina de acción corta y usos de los mismos |
-
2008
- 2008-06-19 ES ES08768636.6T patent/ES2498047T3/es active Active
- 2008-06-19 MX MX2009014052A patent/MX347325B/es active IP Right Grant
- 2008-06-19 AU AU2008266798A patent/AU2008266798B2/en active Active
- 2008-06-19 CA CA2693627A patent/CA2693627C/en active Active
- 2008-06-19 US US12/664,026 patent/US20100190852A1/en not_active Abandoned
- 2008-06-19 EP EP08768636.6A patent/EP2170050B1/en active Active
- 2008-06-19 PL PL08768636T patent/PL2170050T3/pl unknown
- 2008-06-19 WO PCT/US2008/007665 patent/WO2008156820A1/en active Application Filing
- 2008-06-19 JP JP2010513245A patent/JP5421908B2/ja active Active
- 2008-06-19 NZ NZ582033A patent/NZ582033A/en unknown
- 2008-06-19 DK DK08768636.6T patent/DK2170050T3/da active
- 2008-06-19 PT PT87686366T patent/PT2170050E/pt unknown
- 2008-06-19 SI SI200831291T patent/SI2170050T1/sl unknown
- 2008-06-19 CN CN200880020979.1A patent/CN101754678B/zh active Active
- 2008-06-19 BR BRPI0812919A patent/BRPI0812919B8/pt active IP Right Grant
- 2008-06-19 KR KR1020107000124A patent/KR101541557B1/ko active IP Right Grant
-
2010
- 2010-08-03 HK HK10107383.8A patent/HK1140913A1/xx unknown
-
2014
- 2014-06-16 US US14/305,626 patent/US9227918B2/en active Active
- 2014-08-22 HR HRP20140801AT patent/HRP20140801T1/hr unknown
- 2014-09-18 CY CY20141100766T patent/CY1115619T1/el unknown
-
2015
- 2015-11-23 US US14/949,107 patent/US9463179B2/en active Active
-
2016
- 2016-09-12 US US15/262,567 patent/US9737503B2/en active Active
-
2017
- 2017-07-18 US US15/653,367 patent/US10010523B2/en active Active
- 2017-07-18 US US15/653,246 patent/US10010522B2/en active Active
- 2017-07-20 US US15/655,564 patent/US10010524B2/en active Active
-
2018
- 2018-06-04 US US15/997,229 patent/US20180280339A1/en not_active Abandoned
-
2019
- 2019-01-14 US US16/246,980 patent/US20190142781A1/en not_active Abandoned
- 2019-08-29 US US16/555,766 patent/US20190380993A1/en not_active Abandoned
-
2020
- 2020-04-09 US US16/844,440 patent/US20200230097A1/en not_active Abandoned
- 2020-11-12 US US17/096,498 patent/US20210059972A1/en not_active Abandoned
-
2021
- 2021-06-22 US US17/354,288 patent/US20210315855A1/en not_active Abandoned
-
2022
- 2022-01-26 US US17/584,686 patent/US20220142963A1/en not_active Abandoned
-
2023
- 2023-04-24 US US18/138,341 patent/US20230255923A1/en not_active Abandoned
- 2023-12-08 US US18/533,381 patent/US20240115543A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0812919B8 (pt) | composição farmacêutica que compreende um composto e kit | |
BRPI0814737A2 (pt) | Composição, métodos para reduzir, retardar ou de um outro modo inibir o crescimento e/ou replicação de hcv, para prevenir a infecção de uma célula exposta a hcv, para tratar terapeuticamente ou profilaticamente um paciente exposto ou infectado com hcv, e para tratar hepatite c, e, uso de uma composição. | |
CR11731A (es) | Composiciones y procedimientos para su preparación y uso | |
BR112016000898A2 (pt) | Método para parada, proteção e preservação de órgão e redução de lesão de tecido | |
DOP2008000001A (es) | Oxazolidinonas substituidas y su uso | |
AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
CR20140392A (es) | Dihidropirazolonas sustituidas | |
BR112015001419A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
MA28935B1 (fr) | Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite | |
BRPI0507198A (pt) | derivados de bisariluréia | |
AR049518A1 (es) | Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados | |
ECSP10010310A (es) | Nuevos compuestos y composiciones y métodos de uso | |
CO6410279A2 (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
BR112014006220A2 (pt) | composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica | |
RU2009120990A (ru) | Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции | |
WO2009007412A3 (fr) | Deglycation des ages | |
NO20083885L (no) | Fremgangsmate for behandling av inflammatoriske sykdommer | |
BRPI0916936B8 (pt) | composições farmacêuticas, uso de clevidipina e método de reduzir impurezas. | |
BR112016002651A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, combinação, formulação farmacêutica, métodos para exterminar uma micobactéria e/ou inibir a replicação das micobactérias, e para tratar uma infecção e uma doença, e, uso de um composto | |
GT200900319A (es) | (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea | |
WO2009036341A3 (en) | Compositions and methods relating to hiv protease inhibition | |
UY31990A (es) | Nuevos derivados | |
RS54593B1 (en) | Treatment of streptococcal infections | |
BR112013010367A2 (pt) | métodos de prevenir e/ou reduzir a deposição de amiloide e a doença de alzheimer, composição, uso de uma composição, agonista de tlr4 isento de endotoxina, e, uso de uma agonista de tlr4 isento de endotoxina | |
BR112012015386B8 (pt) | composição oftálmica tópica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/01/2019, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |